Marshall Wace
TARA icon

Marshall Wace’s Protara Therapeutics TARA Stock Holding History

Marshall Wace’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Buy
701,021
+650,290
+1,282% +$3.09M ﹤0.01% 1691
2026
Q1 		$264K Sell
50,731
-533,797
-91% -$3.16M ﹤0.01% 2694
2025
Q4 		$3.12M Buy
584,528
+298,942
+105% +$1.66M ﹤0.01% 1370
2025
Q3 		$1.24M Sell
285,586
-76,940
-21% -$249K ﹤0.01% 1850
2025
Q2 		$1.1M Buy
+362,526
New +$1.25M ﹤0.01% 1807
2024
Q4 		– Sell
-77,351
Closed -$142K – 2997
2024
Q3 		$142K Hold
77,351
– – ﹤0.01% 2338
2024
Q2 		$161K Buy
+77,351
New +$226K ﹤0.01% 2340
2021
Q4 		– Sell
-15,190
Closed -$105K – 4269
2021
Q3 		$105K Sell
15,190
-2,279
-13% -$17.8K ﹤0.01% 2885
2021
Q2 		$170K Sell
17,469
-24,667
-59% -$279K ﹤0.01% 2477
2021
Q1 		$664K Buy
+42,136
New +$781K ﹤0.01% 1824

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Marshall Wace's TARA Position: Q2 2026 in Review

Marshall Wace increased its Protara Therapeutics (TARA) stake by 1,282% in Q2 2026, buying an estimated $3.09M and bringing the position to 701,021 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

Marshall Wace first reported a position in TARA in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.12M in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Marshall Wace held 701,021 shares of Protara Therapeutics worth $2.68M as of Q2 2026.
  • Marshall Wace bought 650,290 Protara Therapeutics shares in Q2 2026, an estimated $3.09M.
  • Protara Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1691 holding.
  • Marshall Wace first reported a position in Protara Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Marshall Wace's Protara Therapeutics position peaked at $3.12M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.